NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
TOP NEWS
Pfizer
»26/11/2009 [Company watch]
Pfizer Increases R&D Commitment in China

Pfizer (NYSE: PFE) will expand its China R&D operations by adding facilities in central and western China, according to a Reuters story. The company will build a new clinical R&D center in Wuhan, which will support global clinical drug programs, including Phase I-IV clinical trials. Pfizer did not announce the size of capital commitment to the new R&D center.

 

Pfizer (NYSE: PFE) will expand its China R&D operations by adding facilities in central and western China, according to a Reuters story. The company will build a new clinical R&D center in Wuhan, which will support global clinical drug programs, including Phase I-IV clinical trials. Pfizer did not announce the size of capital commitment to the new R&D center.

Earlier this month, Pfizer announced it would close six of its 20 R&D centers around the world in the wake of its takeover of Wyeth Pharmaceuticals. At the time, we noted the company considered its Shanghai facility to be important enough to shield it from any cutbacks. Now it seems that the company is actually increasing its commitment to performing R&D work in China.

The Wuhan center, which expects to employ 200 people within three years, will also develop research collaborations with local companies.

Pfizer’s Shanghai R&D facility will remain the operations hub for Pfizer’s China R&D activities. The Shanghai center started operations with 14 employees in 2005, a number that grew to 342 by this past summer.

The Wuhan center will be a joint effort between Pfizer (China) Research and Development Co. and its China partner Wuhan National Bioindustry Base Construction and Management Office


AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.